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Background: The purposes of the present study are to evaluate a 
possible genetic factor determining sensitivity to EGFR alterations 
in cases of lung cancers, and also to verify whether such factor can 
be an indicator predicting molecular targeting drugs responsiveness. 
A CA dinucleotide repeats polymorphism of the ﬁrst intron of EGFR 
has recently been reported to be associated with occurrences of EGFR 
transcription in lung cancers, and with EGFR inhibitor responsiveness 
in head and neck cancers. We here examined this polymorphism for 
both tumor and non-tumor tissues of primary lung cancer cases, and 
have analyzed correlations of the polymorphism with EGFR altera-
tions Method: A hundred sixty nine lung tumors and corresponding 
normal parts were subjected to analyses. Locus of ﬁrst intron of EGFR 
covering CA-repeat stretch were PCR-ampliﬁed by using FAM-labeled 
primers. CA-repeats lengths were determined by acrylamide-gel elec-
trophoresis with DNA sequencer (SIMAZU DSQ). 
Results: We found that the constitutional shorter stretch of this repeats 
in the subjects was associated with occurrences of EGFR copy number 
gains (Chi-square test; P = 0.031) in tumors, and that the tumors having 
shorter stretch were more sensitive to geﬁtinib treatment (Chi-square 
test; P = 0.0241). 
Conclusions: We conclude that the CA dinucleotide repeat polymor-
phism can be a genetic factor inﬂuencing occurrences of EGFR copy 
number gains in tumors, and this observation entails the rationale for 
usage of this polymorphism for application of targeting therapy. 
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Background: Geﬁtinib and Erlotinib represent a new class of anti-neo-
plastic agents, the epidermal growth factor receptor (EGFR) Tyrosine 
Kinase inhibitors (TKI). By reversibly occupying the catalytic Mg-ATP 
binding site domain, they interrupt the signaling cascade initiated by 
EGFR stimulation resulting in decreased cell proliferation and survival. 
Clinical trials have demonstrated modest activity with minimal toxicity 
in the setting of advanced NSCLC. Ongoing experience suggests that 
patients who are female, Asian, non-smokers appear to beneﬁt most 
consistently from therapy. We performed a retrospective analysis of 
patients treated with these agents at the Tom Baker Cancer Centre 
(TBCC) to determine if our experience reﬂects this observation.
Methods: The pathology, radiologic records, laboratory investiga-
tions and medical records of 65 patients treated with the EGFR TKIs 
Erlotinib or Geﬁtinib between May 2002 and June 2006 were reviewed. 
Complete or partial radiologic response (CR, PR), stable and progres-
sive disease (SD, PD) were deﬁned as per RECIST criteria. Partial 
response in non-measurable radiologic disease was characterized as 
regression of lymphangitic carcinomatosis. Symptomatic response was 
deﬁned as decreased shortness of breath or pain, decreased FiO2 or 
improvement in ECOG performance status. 
Results: 65 patients, 45 treated with Geﬁtinib, 17 with Erlotinib as 
a ﬁrst EGFR TKI were included; another 3 patients were treated on 
the BR-21 protocol (Erlotinib vs. placebo) as a ﬁrst EGFR TKI and 
subsequently received Geﬁtinib after progressing. 5 patients treated 
with Geﬁtinib as a ﬁrst EGFR TKI, were later treated with Erlotinib. 
Baseline characteristics of the 45 patients treated with Geﬁtinib; 24% 
Asian, 73% Caucasian; 60% female; 29% life long non-smokers, 42% 
ex-smokers, 29% smokers; 56% adenocarcinoma, 13% squamous, 2% 
adenosquamous, 7% large cell, 9% BAC and 13% unknown. 1 patient 
achieved a CR, 6 (13%) had a PR, 16 (36%) had SD with 22 (49%) 
showing PD. Clinically, 13 (29%) patients experienced symptomatic 
improvement, 15 (33%) reported no change, and 17 (38%) patients ex-
perienced symptomatic decline. The 7 responders were predominantly 
non-smoking Asian women with adenocarcinoma. Of the 17 patients 
treated with Erlotinib as a ﬁrst EGFR TKI, baseline characteristics 
were; 24% Asian, 76% Caucasian; 76% female; 41% life long non-
smokers, 29.5% ex-smokers, 29.5% smokers; 65% adenocarcinoma, 
23% squamous, 6% BAC, and 6% other. 2 (12%) patients had a PR, 7 
(41%) had stable disease and the other 8 (47%) patients progressed on 
treatment. Symptomatically, 7 (41%) patients experienced improve-
ment, 6 (35%) had no change, and 4 (24%) experienced symptom 
progression. Both responders were female non-smokers with adenocar-
cinoma, however one was Asian, the other Caucasian. 
Conclusions: At the TBCC, in a select number of patients with ad-
vanced NSCLC, both EGFR TKI’s demonstrated clinical and radio-
logic anti-tumor activity with minimal side effects. The responders to 
both drugs at our institution were predominantly female, non-smoking 
Asians with adenocarcinoma. Our experience in a Canadian setting 
supports the impression that this constellation of clinical characteristics 
is a useful, though not speciﬁc, predictor of response to these agents. 
P3-126 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Erlotinib monotherapy for stage IIIB/IV non-small cell lung 
cancer: A prospective study by the Korean Cancer Study 
Group(KCSG) 
Park, Byeong-Bae1 Ahn, Myung-Ju2 Kim, Sang We3 Kim, Heung-Tae4 
Lee, Jong Seog5 Kang, Jin Hyung6 Cho, Jae Yong7 Song, Hong Suk8 
Sohn, Chang Hak9 Park, Keunchil2 
1 Hanyang University College of Medicine, Seoul, Korea 2 Samsung 
Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
Korea 3 Asan Medical Center, University of Ulsan College of Medicine, 
Seoul, Korea 4 Research Institute and Hospital, National Cancer Cen-
ter, Seoul, Korea 5 Seoul National University Bundang Hospital, Seong-
nam, Korea 6 Kang Nam St. Mary’s Hospital, The Catholic University of 
Korea, Seoul, Korea 7 Yonsei University College of Medicine, Yongdong 
Severance Hospital, Seoul, Korea 8 Keimyung University School of 
Medicine, Daegu, Korea 9 Inje University College of Medicine, Busan, 
Korea 
